Standard BioTools
7100 Shoreline Court
South San Francisco
California
94080
United States
376 articles about Standard BioTools
-
FDA Grants Emergency Use Authorization for Home Collection Kit for Advanta Dx SARS-CoV-2 RT-PCR Assay
3/1/2021
Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the AZOVA™ COVID-19 Test Collection Kit for use with the Fluidigm® Advanta™ Dx SARS-CoV-2 RT-PCR Assay on the company’s Biomark™ HD platform.
-
George Mason University Providing COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platform
2/10/2021
Fluidigm Corporation, an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced that George Mason University in Fairfax, Va., is providing saliva-based COVID-19 testing using the Advanta™ Dx SARS-CoV-2 RT-PCR Assay on the Fluidigm® Biomark™ HD system.
-
Fluidigm Announces Fourth Quarter and Full Year 2020 Financial Results
2/10/2021
Fluidigm Corporation, an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced financial results for the fourth quarter and full year ended December 31, 2020.
-
NIH Sponsored Study at Stanford University School of Medicine to Utilize Fluidigm Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay to Evaluate Immune Responses in Pediatric Patients with COVID-19
2/9/2021
Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Fluidigm® mass cytometry technology and the Maxpar® Direct™ Immune Profiling Assay™ will be used in a longitudinal study of approximately 250 pediatric patients infected with SARS-CoV-2, the virus that causes COVID-19.
-
Fluidigm to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
2/4/2021
Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company’s management will participate in investor meetings at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Thursday, February 18, 2021.
-
Helix Specialty Diagnostics Partners with Genomic LTC DX to Provide COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD PlatformMajor Midwest Labs Targeting 3,000 Tests per Day
1/26/2021
Fluidigm Corporation, an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced that Helix Specialty Diagnostics is partnering with Genomic LTC DX to provide COVID-19 testing using the Advanta™ Dx SARS-CoV-2 RT-PCR Assay on the Fluidigm® Biomark™ HD system.
-
Fluidigm Receives CE-IVD Mark for Its Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19
1/21/2021
Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company has received the CE-IVD mark for its Advanta™ Dx SARS-CoV-2 RT-PCR Assay, an extraction-free saliva-based test to detect nucleic acid from the SARS-CoV-2 virus. The CE-IVD mark is in conformance with the European Union In Vitro Diagnostic Directive. T
-
Fluidigm Announces Conference Call and Webcast of Fourth Quarter and Full Year 2020 Financial Results
1/7/2021
Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report fourth quarter and full year 2020 financial results on Wednesday, February 10, 2021, after the close of the market. Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call and webcast at 2:00 p.m. PT,
-
New Data Published in Gastroenterology Demonstrate the Power of Fluidigm’s Imaging Mass Cytometry on the Hyperion Imaging System to Identify Novel Targets for Pancreatic Cancer Therapy
1/5/2021
Study Highlighting IMC Application in Both Protein and RNA Detection Conducted by Researchers at Fluidigm C enter of Excellence for Imaging Mass Cytometry at Georgetown Lombardi Comprehensive Cancer Center
-
Dr. Ana K. Stankovic, MD, PhD, Appointed to Fluidigm Board of Directors
12/15/2020
Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the appointment of Dr. Ana K. Stankovic, MD, PhD, MSPH, to the company’s Board of Directors.
-
Key Regulatory Body in India Grants Commercial License for Fluidigm Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR AssayFluidigm Assay is Among First Saliva-Based COVID-19 Tests Licensed for Use by Designated Labs in India
11/24/2020
Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the Central Drugs Standard Control Organisation (CDSCO) in India has licensed importation and commercial sale of the Fluidigm® Advanta™ Dx SARS-CoV-2 RT-PCR Assay in that country for COVID-19 testing.
-
Fluidigm to Participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference
11/21/2020
Fluidigm Corporation announced that the company’s management will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Tuesday, December 1, and Wednesday, December 2.
-
Study Utilizing Imaging Mass Cytometry Details Changes in Lung Tissue Architecture at the Single-Cell Level in Patients with COVID-19
11/19/2020
Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that researchers at Weill Cornell Medicine have identified a phenotype of immune cell activity in the lungs of patients infected with SARS-CoV-2, the virus that causes COVID-19, that is distinct from activity observed with other respiratory infections
-
Fluidigm COVID-19 Community Connect Program Builds a Network of Testing Partners to Increase Access of Saliva-Based SARS-CoV-2 Testing for Communities
11/17/2020
Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced COVID-19 Community Connect, a program to link federal, state and local governmental entities, public health agencies, academic institutions, workforces, individuals and a network of high-complexity labs to deliver saliva-based COVID-19 testing.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 17, 2020.
-
Fluidigm to Present at Upcoming Health Care Investor Conference
11/10/2020
Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in investor meetings and present updates regarding Fluidigm’s business strategy and financial performance at the Stifel Virtual Healthcare Conference.
-
Fluidigm Announces Third Quarter 2020 Financial Results
11/5/2020
Fluidigm Corporation, an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced financial results for the third quarter ended September 30, 2020.
-
Fluidigm and Healthvana Partner to Offer COVID-19 Test Results Delivery through Innovative Digital PlatformPatients Receive Results, Education and Next Steps on Their Mobile Phones to Prevent Further Spread of the Disease
11/5/2020
Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it has partnered with Healthvana Inc., the nation’s leading patient platform for delivering COVID-19 test results, to provide clinical laboratory customers utilizing the Fluidigm ® saliva-based Advanta™ Dx SARS-CoV-2 RT-PCR Assay with the option to deliver test resu
-
Fluidigm Mass Cytometry Technologies, Including CyTOF, Imaging Mass Cytometry and Maxpar Direct, Utilized in More than 100 National Clinical Trials25 Trials Utilizing Mass Cytometry Initiated in 2020
11/3/2020
Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that its mass cytometry technologies, including CyTOF ® , Imaging Mass Cytometry (IMC), and Maxpar ® Direct™, have been used in 113 National Clinical Trials listed in the clinicaltrials.gov database. This includes 94 ongoing and 19 completed clinical trials. Twenty-five
-
Dante Labs Launching COVID-19 Testing in Europe Utilizing Fluidigm Pathogen Detection Kit on Biomark HD Platform
11/2/2020
Global Pioneer in Direct-to-Consumer Genomic Testing Chooses Fluidigm Saliva-Based Solution